In the current state of research, numerous literature reports have emphasized the necessity for conducting clinical and epidemiological studies with the objective of evaluating the effects of GLP-1 receptor agonists (GLP-1 RAs) on the clinical outcomes of COVID-19 in patients with type 2 diabetes (T2DM) [8,9]. This evidence concerns the gene GLP1R and COVID-19.